Servier Pharmaceuticals
@ServierPharma
Followers
781
Following
95
Statuses
737
Servier Pharmaceuticals is a U.S. subsidiary of Servier with a focus on oncology treatment and care. See our community guidelines here: https://t.co/tHNeTw4iGH
Boston, MA
Joined September 2018
Adult-type diffuse glioma is a cancer that arises from certain types of brain cells. Symptoms of glioma can be dependent on the type and location of the tumor. Know some of the signs and symptoms and visit our website for more resources:
0
0
0
On Chondrosarcoma Awareness Day, Servier is calling for increased public awareness of chondrosarcoma. Learn more about our Phase 3 clinical trial in patients with IDH1-mutant conventional chondrosarcoma:
0
0
0
Today is World Cancer Day, a time dedicated to raising awareness about cancer prevention and treatment and to shine a light on the millions of lives impacted by the disease every year.
0
0
2
We’re proud to announce that Servier is a finalist for the 2025 Edison Best New Product Awards™ in the Advancements in Neurological Treatments category. We’re honored to have our recent approval recognized and look forward to the award ceremony in April.
0
0
5
Genetic mutations have an impact on glioma classification and potential prognosis. Testing for an IDH mutation in all patients with glioma is essential based on the current guidelines. Learn more:
0
0
4
Approximately 16,000 cases of myelodysplastic syndromes (MDS) are reported in the US each year. Learn more about this blood cancer & our commitment to research: #MDS #bloodcancer
0
0
2
Reminder: Servier’s Golden Ticket Contest closes February 7th! One organization will win shared lab space and services, as well as access to Servier’s team of experts. Learn more about the contest and how to enter here:
0
0
0
Susan Pandya, M.D., Vice President, Clinical Development and Global Head of Oncology LS/LCM recently discussed the essential role of mutational testing in acute myeloid leukemia (#AML) treatment and how mutations can impact prognosis. Read more here:
0
0
3
Congratulations to Servier’s Kelly Schlemm, Vice President and Head of Corporate Affairs, on being honored as one of @RaganComms Top Women in Communications in the “Leader” category!
0
0
2
Today, we are proud to share updates on two Phase 3 pivotal studies within our development program for IDH1-mutated cancers in both hematological malignancies and solid tumors. Learn more:
0
0
3
Goodbye 2024! We are reflecting on a year filled with groundbreaking milestones, impactful partnerships, and our patient-forward mission continuing to come to fruition.
0
0
1
We advocate for patients to have the information they need to receive personalized care. Visit our website for glioma statistics, resources, and more:
0
0
2
Every case represents a life we aim to change. We’re committed to raising awareness and delivering transformative therapies for the thousands of people diagnosed with AML and MDS each year. Learn more:
0
0
2
‘Tis the season of giving, and we are proud to support nonprofit organizations that support our local communities. This year, we provided support to @CITCBoston, a volunteer organization that ensures all children experience holiday magic.
0
0
0
Approximately 50% of AML patients have mutations that can guide the use of targeted therapies by physicians. Read more from Susan Pandya, M.D., VP, Clinical Development and Global Head of Oncology LS/LCM, on the essential role of mutational testing.
0
0
1
#ASH24 was a powerful reminder of the importance of our mission. Hear more from our CEO, David K. Lee, on the impact of conferences like ASH and explore our latest hematology research here:
0
0
1
As the leader in IDH-mutant targeted therapies, we continue to advance research against aggressive cancers like IDH1-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). See the data we shared at #ASH24
0
0
4
Acute myeloid leukemia (AML) is the most common acute leukemia affecting adults. Learn more about AML and stay tuned for our latest data to be shared at #ASH24:
0
0
0